Congestive Heart Failure denials in California external review
In the California DMHC record, independent physician reviewers decided 46 published external-review cases involving congestive heart failureand overturned the plan’s denial in 32.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for congestive heart failure
| Category | Decisions | Overturned |
|---|---|---|
| Zoll Life Vest | 4 | 25% |
| Wearable Cardioverter Defibrillator | 4 | 50% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 23 | 21.7% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 22 | 40.9% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested a LifeVest wearable cardiovascular defibrillator for treatment of the enrollee’s medical condition. Findings: Two physician reviewers found that the patient was presented with three week history of increasing dyspnea on exertion progressing to dyspnea at rest, orthopnea and paroxysmal nocturnal dyspnea. He presented with a new onset atrial fibrillation with rapid ventricular response. The patient underwent transthoracic echocardiogram and transesophageal echo (TEE) which revealed moderately severe global left ventricular (LV) dysfunction, moderately severe mitral insufficiency and left atrial appendage thrombus. The patient also underwent cardiac nuclear study which did not show active ischemia.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for LifeVest Wearable Cardioverter Defibrillator (WCD) billed by Zoll Services. This patient presented with newly diagnosed congestive heart failure. The patient was referred for a LifeVest WCD. The provider noted that the patient did not complete three months of guideline directed medical therapy and had an estimated high risk of sudden cardiac death that had the potential to progress over time. Per the current American Heart Association (AHA) guidelines, the use of a WCD for primary prevention of sudden cardiac death is appropriate in patients with non-ischemic cardiomyopathy with left ventricle ejection fraction (LVEF) of 30% or less, on chronic optimal medical therapy.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for a wearable cardiovascular defibrillator (Zoll LifeVest) provided Findings: The physician reviewer found that The patient is a patient with a history of smoking, obstructive pulmonary disease and diabetes. The patient presented with dyspnea symptoms due to congestive heart failure. The patient was evaluated with severely depressed left ventricular ejection fraction and subsequent cardiac catheterization. The report noted normal coronary arteries without stenosis. The patient was medically managed and discharged with a wearable defibrillator. A follow up visit reported fatigue and exertional dyspnea. An echocardiogram later reported a left ventricular ejection fraction of 15%. An implantable defibrillator was placed .
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage to remain in a skilled nursing facility and continue physical therapy for treatment of the enrollee, who has a history of congestive heart failure. Findings: The physician reviewer found that This patient has a history of dilated cardiomyopathy with an ejection fraction of 20-25% and New York Heart Association (NYHA) class III-IV congestive heart failure. He has had multiple episodes of volume overload in the last year requiring intensive diuresis. He was hospitalized with volume overload and pneumonia. He was aggressively treated in the hospital over a week and medically stabilized. He has been receiving care at the skilled nursing facility, primarily for deconditioning. He had made very modest functional progress.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving congestive heart failure, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY